{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:29:41Z","timestamp":1787959781571,"version":"build-2784847793"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psychedelic-assisted therapy (PAT) is an emerging complex intervention for psychiatric and existential conditions (i.e., forms of distress related to meaning, mortality, and identity, such as that arising in life-threatening illness); however, a systematic characterization of the evaluation methods used across the entire clinical intervention remains incomplete. This scoping review synthesizes the scientific literature on the methodologies and frameworks for evaluating PAT, covering pre-session screening, acute experience, intervention processes, post-session integration, clinical and existential outcomes, safety, and service evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines, we analyzed 59 peer-reviewed publications, comprising contemporary PAT literature published between 2008 and 2026 and foundational psychometric sources for established instruments used in PAT. The findings were categorized into four evaluation domains: (i) assessment instruments for subjective experiences; (ii) clinical intervention models and competency frameworks; (iii) clinical and existential outcome measures; and (iv) safety, ethics, and implementation frameworks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis reveals a number of advances, including the development and cross-cultural adaptation of validated instruments for measuring mystical and challenging experiences. Clinical intervention frameworks emphasizing the importance of the \u201ctherapeutic container\u201d have been articulated, and preliminary work has begun to identify core practitioner competencies. PAT has been associated with preliminary findings from controlled studies for conditions such as depression, anxiety, post-traumatic stress disorder, and existential distress, although demographic representation in trials remains limited, and methodological constraints (e.g., small samples and challenges in blinding) warrant cautious interpretation. The review also identifies gaps: methodological integration is still incomplete, with different assessment domains rarely combined into unified protocols; measures for post-session integration and existential outcomes remain undervalidated; and safety monitoring and implementation science present areas requiring standardization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This review maps the current methodological landscape, documenting areas of advancement and defining priorities for developing the integrated, multidimensional evaluation models required to advance the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1880744","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:32:25Z","timestamp":1785994345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Maria Laura","family":"Mele","sequence":"first","affiliation":[{"name":"My\u00e8sis Insight Center, Center for Research and Psychotherapy","place":["Rome, Italy"]},{"name":"Societ\u00e0 Italiana di Medicina Psichedelica (SIMEPSI), Italian Society for Psychedelic Medicine","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Federici","sequence":"additional","affiliation":[{"name":"My\u00e8sis Insight Center, Center for Research and Psychotherapy","place":["Rome, Italy"]},{"name":"Department of Philosophy, Social and Human Sciences and Education, University of Perugia","place":["Perugia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1769878","article-title":"A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J Psychoact Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015383.pub2","article-title":"Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases","volume":"9","author":"Schipper","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251381074","article-title":"Psychedelic-assisted therapy as a complex intervention: Implications for clinical trial design","volume":"15","author":"Muthukumaraswamy","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3","article-title":"Mdma-assisted therapy for severe ptsd: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: A paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1505894","article-title":"Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy","volume":"16","author":"Zamaria","year":"2025","journal-title":"Front Psychol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/02791072.2024.2424272","article-title":"Masking influences: A systematic review of placebo control and masking in psychedelic studies","volume":"58","author":"Barstowe","year":"2026","journal-title":"J Psychoactive Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacol (Berl)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.866018","article-title":"Models of psychedelic-assisted psychotherapy: A contemporary assessment and an introduction to embark, a transdiagnostic, trans-drug model","volume":"13","author":"Brennan","year":"2022","journal-title":"Front Psychol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatrica Scandinava"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/psychoactives4030021","article-title":"Increasing the evaluation and reporting rigor of psychotherapy interventions in treatments involving psychedelics","volume":"4","author":"Fradet","year":"2025","journal-title":"Psychoactives"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2125467","article-title":"Scoping review of experiential measures from psychedelic research and clinical trials","volume":"55","author":"Herrmann","year":"2023","journal-title":"J Psychoact Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/02698811231200019","article-title":"Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics","volume":"38","author":"Hovmand","year":"2024","journal-title":"J Psychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","article-title":"Classical psychedelics for the treatment of depression and anxiety: A systematic review","volume":"258","author":"Muttoni","year":"2019","journal-title":"J Affect Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S2215-0366(24)00333-X","article-title":"Quality of reporting on psychological interventions in psychedelic treatments: A systematic review","volume":"12","author":"Seybert","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/m18-0850","article-title":"Prisma extension for scoping reviews (Prisma-Scr): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Internal Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291724002204","article-title":"Validation of the imperial psychedelic predictor scale","volume":"54","author":"Angyus","year":"2024","journal-title":"Psychol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02105408","article-title":"The development of a clinician-administered ptsd scale","volume":"8","author":"Blake","year":"1995","journal-title":"J Traumatic Stress"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.863247","article-title":"The psychedelic integration scales: Tools for measuring psychedelic integration behaviors and experiences","volume":"13","author":"Frymann","year":"2022","journal-title":"Front Psychol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1037\/0022-0167.36.2.223","article-title":"Development and validation of the working alliance inventory","volume":"36","author":"Horvath","year":"1989","journal-title":"J Couns Psychol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1038\/s41598-024-53829-z","article-title":"Development and psychometric validation of a novel scale for measuring \u2018psychedelic preparedness\u2019","volume":"14","author":"McAlpine","year":"2024","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1207\/S15324796ABM2401_06","article-title":"Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy\u2014spiritual well-being scale (Facit-Sp)","volume":"24","author":"Peterman","year":"2002","journal-title":"Ann Behav Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12456","article-title":"Development of the Japanese version of the challenging experience questionnaire","volume":"44","author":"Tani","year":"2024","journal-title":"Neuropsychopharmacol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06187-5","article-title":"The Watts Connectedness Scale: A new scale for measuring a sense of connectedness to self, others, and world","volume":"239","author":"Watts","year":"2022","journal-title":"Psychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12377","article-title":"Development of the Japanese version of the 30-item mystical experience questionnaire","volume":"44","author":"Yonezawa","year":"2024","journal-title":"Neuropsychopharmacol Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/10499091221147700","article-title":"An integrative review of measures of spirituality in experimental studies of psilocybin in serious illness populations","volume":"40","author":"Baker","year":"2023","journal-title":"Am J Hospice Palliative Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-06049-6","article-title":"Assessing the risk-benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research","volume":"239","author":"Bender","year":"2022","journal-title":"Psychopharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/02698811231215420","article-title":"Older adults in psychedelic-assisted therapy trials: A systematic review","volume":"38","author":"Bouchet","year":"2024","journal-title":"J Psychopharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0007","article-title":"A systematic review of reporting practices in psychedelic clinical trials: Psychological support, therapy, and psychosocial interventions","volume":"1","author":"Brennan","year":"2023","journal-title":"Psychedelic Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/psychoactives4040035","article-title":"Digital enablement of psychedelic-assisted therapy in non-clinical settings: A systematic review of safety, efficacy, and implementation models","volume":"4","author":"Driscoll","year":"2025","journal-title":"Psychoactives"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2024.112020","article-title":"Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review","volume":"189","author":"Ferreira","year":"2025","journal-title":"J Psychosomatic Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v13.i5.182","article-title":"Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review","volume":"13","author":"Fonseka","year":"2023","journal-title":"World J Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241289024","article-title":"The safety of psilocybin-assisted psychotherapy: A systematic review","volume":"59","author":"Freitas","year":"2025","journal-title":"Aust New Z J Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000002275","article-title":"Psychedelic-assisted therapy and psychedelic science: A review and perspective on opportunities in neurosurgery and neuro-oncology","volume":"92","author":"Kelly","year":"2023","journal-title":"Neurosurgery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.16421","article-title":"Psychedelic therapy in depression and substance use disorders","volume":"60","author":"Korkmaz","year":"2024","journal-title":"Eur J Neurosci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02800-5","article-title":"Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies","volume":"30","author":"Sabe","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.05.002","article-title":"Do classic psychedelics increase the risk of seizures? A scoping review","volume":"85","author":"Soto-Angona","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251384513","article-title":"Biological markers of treatment response to serotonergic psychedelic therapies: A systematic review","volume":"15","author":"Wong","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02271-0","article-title":"Neuroimaging in psychedelic drug development: Past, present, and future","volume":"28","author":"Wall","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15010253","article-title":"Efficacy and safety of psychedelics in mental disorder cases: An umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Dominiak","year":"2025","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2025.07.020","article-title":"A dose of therapy with psilocybin - a meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy","volume":"96","author":"Hultgren","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2022.00219","article-title":"Reasonable expectations for replications of psychedelic-assisted therapy: The case for prediction intervals rather than p-values","volume":"6","author":"Earleywine","year":"2023","journal-title":"J Psychedelic Stud"},{"key":"B48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jad.2023.03.083","article-title":"The need for establishing best practices and gold standards in psychedelic medicine","volume":"332","author":"Feduccia","year":"2023","journal-title":"J Affect Disord"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251395232","article-title":"Corrigendum to \u201cPsychedelic assisted therapy as a complex intervention: Implications for clinical trial design","volume":"15","author":"Muthukumaraswamy","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251340929","article-title":"Psychedelic-assisted psychotherapy: The need to monitor adverse events","volume":"39","author":"Schruers","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2026.112170","article-title":"Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin","volume":"192","author":"Zuljevic","year":"2026","journal-title":"J Clin Epidemiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13643-022-01930-7","article-title":"The psychological processes of classic psychedelics in the treatment of depression: A systematic review protocol","volume":"11","author":"Johansen","year":"2022","journal-title":"Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s40501-025-00368-7","article-title":"The Thrive model of psychedelic integration: A holistic framework bridging indigenous knowledge and evidence-based practice","volume":"12","author":"Adkins Singh","year":"2025","journal-title":"Curr Treat Options Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/philosophies8050076","article-title":"Ethics of psychedelic use in psychiatry and beyond\u2014drawing upon legal, social and clinical challenges","volume":"8","author":"Azevedo","year":"2023","journal-title":"Philosophies"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241240597","article-title":"A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia","volume":"58","author":"Hatfield","year":"2024","journal-title":"Aust New Z J Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103517","article-title":"Considerations and cautions for the integration of psilocybin into routine clinical care: A consensus statement from the US National Network of Depression Centers\u2019 Task Group on Psychedelics and Related Compounds","volume":"89","author":"Hosein","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.genhosppsych.2025.09.003","article-title":"Key competencies for psychedelic treatment in real-world mental health care settings","volume":"97","author":"Wolff","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119866","article-title":"Development of an Australian clinical practice guideline on methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder","volume":"391","author":"Yong","year":"2025","journal-title":"J Affect Disord"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06907-7","article-title":"Provider perspectives on challenges in treatment during psychedelic therapy","author":"Bender","year":"2025","journal-title":"Psychopharmacology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"Hope: A pilot study of psilocybin enhanced group psychotherapy in patients with cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manage"},{"key":"B62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/psymed.2023.0033","article-title":"Getting in touch with touch: The importance of studying touch in MDMA-assisted therapy and the development of a new self-report measure","volume":"2","author":"Luoma","year":"2024","journal-title":"Psychedelic Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2024.0346","article-title":"Ketamine and ketamine-assisted psychotherapy for psychiatric and existential distress in patients with serious medical illness: A narrative review","volume":"28","author":"Sholevar","year":"2025","journal-title":"J Palliative Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1880744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:32:26Z","timestamp":1785994346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1880744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":64,"alternative-id":["10.3389\/fpsyt.2026.1880744"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1880744","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1880744"}}